About Amgen Business Development
Amgen Business Development is a venture capital firm founded in 2004. It is primarily based out of Thousand Oaks, United States. As of Nov 2025, Amgen Business Development is an active investor, having invested in 63 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series B round of AAVantgarde Bio Overall, Amgen Business Development portfolio has seen 14 IPOs and 24 acquisitions including key companies like Amgen, Sutro Biopharma and Cytokinetics. A lot of funds co-invest with Amgen Business Development, with names like New Enterprise Associates sharing a substantial percentage of its portfolio. Amgen Business Development has team of 33 people including 10 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 5 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Amgen Business Development's List of Top Investments
Amgen Business Development has a portfolio of 63 companies. Their most notable investments are in Ardelyx and Immatics.Their portfolio spans across United States, Germany, Canada and 8 more locations. They have invested in Life Sciences, High Tech, HealthTech and 7 other sectors, across stages such as Series B, Series A and 5 more. Here is the list of top investments by Amgen Business Development:1. Amgen
Developer of pharmaceutical products for treating multiple diseases. It manufactures and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology, and inflammation. In 2022, the company recorded annual revenues of $26.32B and a net profit of $6.55B.
Key facts about Amgen
- Founded Year: 1980
- Location: Thousand Oaks (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Employee Count: 40,369 as on Apr 30, 2026
- Investors: Digital Pharma Lab, Amgen Business Development and 11 Others
- Latest Funding Round: Post IPO, Mar 12, 2012, $*****
- Highlight: Public
Developer of antibody-based therapeutics for cancer therapy. The company uses cell-free protein synthesis platform XpressCF technology led to the discovery of STRO-001 and STRO-002, for B-cell malignancies, ovarian and endometrial cancers.
Key facts about Sutro Biopharma
- Founded Year: 2003
- Location: United States
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $175M
- Employee Count: 211 as on Apr 30, 2026
- Investors: Amgen Business Development, Celgene and 17 Others
- Latest Funding Round: Series E, Jul 26, 2018, $*****
- Highlight: Public
3. MIT
Key facts about MIT
- Founded Year: 1861
- Location: United States
- Stage: Seed
- Total Funding till date: $4M
- Employee Count: 11,888 as on Dec 31, 2022
- Investors: Amgen Business Development, Howells-Barby Ventures and 19 Others
- Latest Funding Round: Grant (prize money), Dec 30, 2025, $*****
4. Cytokinetics
Developer of muscle activators as potential treatments for debilitating diseases. Its drug pipeline includes Omecamtiv mecarbil, a novel activator of cardiac myosin, the motor protein that powers cardiac muscle contraction and is being investigated as a potential treatment for heart failure in collaboration with Amgen. Also developing CK-2127107 (CK-107), a novel skeletal muscle troponin activator as a potential treatment for people living with spinal muscular atrophy (SMA).
Key facts about Cytokinetics
- Founded Year: 1997
- Location: San Francisco (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $60M
- Employee Count: 767 as on May 31, 2026
- Investors: Foresite Capital, Amgen Business Development and 12 Others
- Latest Funding Round: Post IPO, Jul 01, 2022, $*****
- Highlight: Public
5. Kite Pharma
Developer of cancer immunotherapy products using genetic engineering. The company's product Yescarta a CAR-T therapy for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma and TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Key facts about Kite Pharma
- Founded Year: 2009
- Location: Los Angeles (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2024
- Stage: Acquired
- Total Funding till date: $97.7M
- Employee Count: 3,991 as on May 31, 2026
- Investors: Amgen Business Development, Pontifax and 10 Others
- Latest Funding Round: Post IPO, Apr 03, 2018, $*****
- Highlight: Acquired
Amgen Business Development's Year-on-Year Investment Trends
Amgen Business Development has invested in 63 companies over the last 19 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in AAVantgarde Bio and most recent follow-on round was in Informed Mindset Medical.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 0 | 1 | 1 |
2023 | 0 | 0 | 0 |
2022 | 2 | 0 | 2 |
2021 | 2 | 0 | 2 |
2020 | 1 | 2 | 3 |
2019 | 2 | 1 | 3 |
2018 | 3 | 5 | 8 |
2017 | 6 | 0 | 6 |
Amgen Business Development's Investments by Stage
Amgen Business Development has made 13 investments in Series B stage with an average round size of $49.7M, 11 investments in Series A stage with an average round size of $22.4M and 4 investments in Series C stage with an average round size of $63M.Stage of entry | No. of Investments |
|---|---|
Series B | 13 |
Series A | 11 |
Series C | 4 |
Post IPO | 3 |
Seed | 3 |
Others | 3 |
Note: We have considered here, only first round of investments
Amgen Business Development's Investments by Sector
Amgen Business Development has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Vertical SaaS. Notably, it has invested in 52 Tech companies, 46 Enterprise (B2B) companies, 12 Software companies and at least 3 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 33 |
High Tech | 8 |
HealthTech | 7 |
Enterprise Applications | 6 |
Vertical SaaS | 3 |
Others | 2 |
Note: We have considered here, only first round of investments
Amgen Business Development's Investments by Geography
Amgen Business Development has made most investments in United States (31), followed by Canada where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 31 |
Canada | 2 |
Germany | 1 |
Italy | 1 |
Singapore | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Amgen Business Development's recent investments
Amgen Business Development has not made any investment in 2026 so far.Here are the most recent investments by Amgen Business Development:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 03, 2025 | Italy | Series B | 3494 | [+11] | |
Mar 20, 2024 | United States | Series A | 2261 | [+2] | |
Oct 17, 2022 | Canada | Series C | 2205 | ||
Jun 30, 2022 | United States | Series B | 8024 | [+7] | |
May 17, 2021 | Singapore | Series C | 5969 | [+13] |
IPOs and Publicly Listed companies in Amgen Business Development's Portfolio
14 of Amgen Business Development's portfolio companies have become public. NexImmune got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2021 at marketcap of $127M and Kymeratx got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $863M.Here are Amgen Business Development's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 12, 2021 | Jul 24, 2014 | Series A | 5934 | |
Aug 21, 2020 | Oct 30, 2017 | Series A | 6061 | |
Jul 02, 2020 | Oct 04, 2017 | Series E | 2946 | |
Mar 28, 2019 | May 12, 2015 | Series A | 7752 | |
Feb 07, 2019 | Jan 07, 2016 | Series D | 2927 |
Acquired companies in Amgen Business Development's Portfolio
24 companies from Amgen Business Development's portfolio have been acquired. The most recent acquisition was Kezar Life Sciences in Mar 2026 by Aurinia Pharmaceuticals for $*****.Here are Amgen Business Development's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 30, 2026 | - | - | 3877 | |
May 15, 2025 | Feb 05, 2019 | Series B | 7613 | |
Jan 13, 2025 | Nov 14, 2017 | Series D | 3400 | |
May 29, 2024 | Jul 20, 2016 | Series B | 5037 | |
Nov 21, 2023 | Nov 26, 2018 | Series A | 7600 |
_1582604151324.jpeg?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Amgen Business Development
Amgen Business Development has a team of 33 members including 10 Partners and 8 Principals located in United States and Switzerland. Amgen Business Development's team does not sit on the board of any company as of now.Here is a list of top team members in Amgen Business Development:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Thousand Oaks | - | - | |
Partner | Zug | - | - | |
Partner | Ventura | - | - | |
Partner | Los Angeles | - | - | |
Partner | United States | - | - | |
Partner | Los Angeles | - | - | |
Partner | United States | - | - | |
Partner | Los Angeles | - | - | |
Partner | United States | - | - | |
Partner | Los Angeles | - | - | |
Principal | Rockville | - | - |
Co-investors of Amgen Business Development
Over the past 19 years, 344 investors have co-invested in Amgen Business Development's portfolio companies. This includes funds and angels.
- Invested before Amgen Business Development: HHS, Atlas Venture and 93 others have invested in rounds before Amgen Business Development. There are 4 companies where HHS has invested before Amgen Business Development and 3 companies where Atlas Venture has invested before Amgen Business Development.
- Top Co-investors of Amgen Business Development: 105 investors entered a company along with Amgen Business Development. These include investors like New Enterprise Associates (5 companies).
- Invested after Amgen Business Development: A total of 144 investors have invested in Amgen Business Development's portfolio after their investments. Top Investors include Foresite Capital (5 companies), Amgen (4 companies) and Citadel (3 companies).
Recent News related to Amgen Business Development
•
Quantinuum Secures $600 Million Capital at $10 Billion ValuationQuantum Computing Report•Sep 05, 2025•Quantinuum, JPMorgan Chase, Mitsui, Quanta Computer and 16 others
•
•
Casma Therapeutics Raises $46.0 M in Series C FundingBusiness Wire•Nov 15, 2022•Casma Therapeutics, Amgen Business Development, Astellas Venture Management, Eisai and 9 others
•
BigHat Biosciences Raises $75 Million in Series B Funding to Design Safer, More Effective AntibodiesBusiness Wire•Jul 20, 2022•BigHat, Section 32, AME Cloud Ventures, 8VC and 9 others
•
•
CancerIQ Closes $14M Series B Funding RoundGenomeWeb•Mar 03, 2022•CancerIQ, Merck Global Health Innovation Fund, Amgen, McKesson Ventures and 4 others
•
Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform". Leverkusen & South San Francisco, CA.Life-Sciences-Germany•Jan 06, 2021•Senti Bio, Bayer, Matrix Partners, Mirae Asset Capital Markets and 20 others
•
Imago BioSciences impresses with $80m series CGlobal Corporate Venturing•Nov 23, 2020•Imago BioSciences, Pharmaron, MRLV, Amgen Business Development
•
Aetion Raises Further $19M; Closes $82M Series B RoundFinSMEs•Aug 26, 2020•Aetion, Johnson & Johnson Innovation, Greenspring Associates, EDBI and 11 others
•
Syapse Raises $30M in Equity FundingGenomeWeb•May 28, 2020•Syapse, Amgen Business Development, Ascension Ventures, Intermountain Healthcare and 4 others
